Dulaglutide
Indication
Treatment of type 2 diabetes mellitus in adults to improve glycaemic control
Green
Brand:
Trulicity ®
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Endocrine system
Background
The GLP‑1 agonist Dulaglutide is indicated in adults with type 2 diabetes mellitus to improve glycaemic control.
NICE Guideline 28 only recommends the prescribing of GLP‑1 agonists in the add-on therapy setting; therefore dulaglutide was reviewed only in the add-on therapy setting.
Dulaglutide is a drug appropriate for initiation and ongoing prescribing in both primary and secondary care when prescribed in line with NICE Guideline 28 after second intensification of therapy fails to achieve targets combined with metformin and a sulfonylurea or combined with insulin at second intensification of treatment in patients who cannot take metformin.
Dulaglutide may only be continued if the person has a beneficial metabolic response, as defined in NICE Guideline 28.
The LSCMMG recommends dulaglutide as a 1st line GLP‑1 agonist.
Recommendation
LSCMMG Recommendation:
Green
Reason for decision:
Suitable for initiation in primary care
Supporting documents: